Trent Lund resumes & CV records
Resumes
Trent L Lund, Age 545020 S Del Rio St, Salt Lake City, UT 84117
Trent Lund Phones & Addresses
5020 S Del Rio St, Salt Lake Cty, UT 84117
6010 Lodestone Ave, Salt Lake City, UT 84118 (801) 965-0137
West Valley City, UT
Magna, UT
Midvale, UT
Social networks
Trent L Lund
Linkedin
Mentions for Trent L Lund
Publications & IP owners
Us Patents
Use Of Equol For Treating Androgen Mediated Diseases
US Patent:
8450364, May 28, 2013
Filed:
Apr 9, 2012
Appl. No.:
13/442466
Inventors:
Edwin Douglas Lephart - Orem UT, US
Trent D. Lund - Wheaton IL, US
Kenneth David Reginald Setchell - Cincinnati OH, US
Robert J. Handa - Fort Collins CO, US
Trent D. Lund - Wheaton IL, US
Kenneth David Reginald Setchell - Cincinnati OH, US
Robert J. Handa - Fort Collins CO, US
Assignee:
Brigham Young University - Provo UT
Colorado State University Research Foundation - Fort Collins CO
Children's Hospital Medical Center of Cincinnati, Ohio - Cincinnati OH
Colorado State University Research Foundation - Fort Collins CO
Children's Hospital Medical Center of Cincinnati, Ohio - Cincinnati OH
International Classification:
A61K 31/35
US Classification:
514456
Abstract:
Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
Use Of Equol For Treating Skin Diseases
US Patent:
2005024, Nov 3, 2005
Filed:
Feb 17, 2005
Appl. No.:
11/059951
Inventors:
Edwin Lephart - Orem UT, US
Trent Lund - Wheaton IL, US
Kenneth Reginald Setchell - Cincinnati OH, US
Robert Handa - Fort Collins CO, US
Trent Lund - Wheaton IL, US
Kenneth Reginald Setchell - Cincinnati OH, US
Robert Handa - Fort Collins CO, US
International Classification:
A61K031/56
US Classification:
514170000
Abstract:
Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.
Use Of Equol For Treating Androgen Mediated Diseases
US Patent:
2006012, Jun 8, 2006
Filed:
Oct 29, 2003
Appl. No.:
10/533045
Inventors:
Edwin Lephart - Orem UT, US
Trent Lund - Wheaton IL, US
Kenneth David Setchell - Cincinnati OH, US
Robert Handa - Fort Collins CO, US
Trent Lund - Wheaton IL, US
Kenneth David Setchell - Cincinnati OH, US
Robert Handa - Fort Collins CO, US
International Classification:
A61K 31/353
US Classification:
514456000
Abstract:
Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
Use Of Equol For Treating Androgen Mediated Diseases
US Patent:
2010008, Apr 8, 2010
Filed:
Oct 2, 2009
Appl. No.:
12/572791
Inventors:
Edwin Douglas Lephart - Orem UT, US
Trent D. Lund - Wheaton IL, US
Kenneth David Reginald Setchell - Cincinnati OH, US
Robert J. Handa - Fort Collins CO, US
Trent D. Lund - Wheaton IL, US
Kenneth David Reginald Setchell - Cincinnati OH, US
Robert J. Handa - Fort Collins CO, US
International Classification:
A61K 31/353
A61P 43/00
A61P 43/00
US Classification:
514456
Abstract:
Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
Use Of Equol For Treating Androgen Mediated Diseases
US Patent:
2016025, Sep 8, 2016
Filed:
Mar 9, 2016
Appl. No.:
15/065344
Inventors:
Edwin Douglas Lephart - Orem UT, US
Trent D. Lund - Wheaton IL, US
Robert J. Handa - Fort Collins CO, US
Trent D. Lund - Wheaton IL, US
Robert J. Handa - Fort Collins CO, US
International Classification:
A61K 31/353
A61K 9/00
A61K 8/49
A61Q 19/08
A61Q 7/00
A61K 9/00
A61K 8/49
A61Q 19/08
A61Q 7/00
Abstract:
Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
Use Of Equol For Treating Androgen Mediated Diseases
US Patent:
2015034, Dec 3, 2015
Filed:
Jul 27, 2015
Appl. No.:
14/810117
Inventors:
Edwin Douglas Lephart - Orem UT, US
Trent D. Lund - Wheaton IL, US
Robert J. Handa - Fort Collins CO, US
Trent D. Lund - Wheaton IL, US
Robert J. Handa - Fort Collins CO, US
International Classification:
A61K 31/353
A23L 1/30
A23L 1/30
Abstract:
Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
Use Of Equol Of Treating Androgen Mediated Diseases
US Patent:
2014013, May 15, 2014
Filed:
May 28, 2013
Appl. No.:
13/903748
Inventors:
Edwin Douglas Lephart - Orem UT, US
Trent D. Lund - Wheaton IL, US
Kenneth David Reginald Setchell - Cincinnati OH, US
Robert J. Handa - Fort Collins CO, US
Trent D. Lund - Wheaton IL, US
Kenneth David Reginald Setchell - Cincinnati OH, US
Robert J. Handa - Fort Collins CO, US
Assignee:
Brigham Young University - Provo UT
Children's Hospital Center - Cincinnati OH
Colorado State University Research Foundation - Fort Collins CO
Children's Hospital Center - Cincinnati OH
Colorado State University Research Foundation - Fort Collins CO
International Classification:
A61K 31/352
US Classification:
514456
Abstract:
Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
Use Of Equol For Treating Skin Diseases
US Patent:
2010007, Mar 25, 2010
Filed:
Jul 31, 2009
Appl. No.:
12/533169
Inventors:
Edwin Douglas Lephart - Orem UT, US
Trent D. Lund - St. Charles IL, US
Kenneth David Reginald Setchell - Cincinnati OH, US
Robert J. Handa - Phoenix AZ, US
Trent D. Lund - St. Charles IL, US
Kenneth David Reginald Setchell - Cincinnati OH, US
Robert J. Handa - Phoenix AZ, US
International Classification:
A61K 31/352
A61P 5/26
A61P 5/26
US Classification:
514456
Abstract:
Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.
NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.